President Donald Trump has signed an executive order (EO) to ease restrictions on the use of psychedelic drugs to treat serious mental illness, including post-traumatic stress disorder and brain trauma.
The EO directs the commissioner of the US Food and Drug Administration (FDA) to provide Commissioner’s National Priority Vouchers
Register for free to keep reading
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day